Medical devices can be ultra reliable, lucrative business, but there are plenty of ways for companies to blow it, too.
News & Analysis: Insulet
In the first quarter, the tubeless insulin pump specialist's revenue growth accelerated and it raised its full-year 2019 guidance.
The insulin pump maker reported better-than-expected first-quarter financials and issued a rosier outlook for 2019.
PODD earnings call for the period ending March 31, 2019.
Find out why our Motley Fool contributors called out these three businesses as top opportunities right now.
The leader in tubeless insulin pump technology acheived full-year profitability for the first time in 2018.
In the fourth quarter, the tubeless insulin pump specialist grew revenue 26% year over year.
PODD earnings call for the period ending December 31, 2018.
Innovative insulin pumps and promising drugs make these three companies worthy of investors' attention.
Here's why these mid-cap stocks look enticing.